James Noble
2018
In 2018, James Noble earned a total compensation of $2.6M as Chief Executive Officer at Adaptimmune Therapeutics, a 58% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $250,585 |
|---|---|
| Option Awards | $1,826,960 |
| Salary | $536,011 |
| Other | $27,957 |
| Total | $2,641,513 |
Noble received $1.8M in option awards, accounting for 69% of the total pay in 2018.
Noble also received $250.6K in non-equity incentive plan, $536K in salary and $28K in other compensation.
Rankings
In 2018, James Noble's compensation ranked 4,423rd out of 14,244 executives tracked by ExecPay. In other words, Noble earned more than 68.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,423 out of 14,244 | 69th |
Division Manufacturing | 1,654 out of 5,765 | 71st |
Major group Chemicals And Allied Products | 595 out of 2,128 | 72nd |
Industry group Drugs | 498 out of 1,817 | 73rd |
Industry Biological Products, Except Diagnostic Substances | 96 out of 339 | 72nd |
Pay ratio
| James Noble's Pay | $2,641,513 |
|---|---|
| Median Employee's Pay | $137,800 |
| Pay Ratio | 19to 1 |
In 2018, the annual total compensation of James Noble was $2,641,513.
The annual total compensation of the median employee at Adaptimmune Therapeutics was $137,800.
The ratio of James Noble's pay to the pay of median employee was therefore 19 to one.
Source: SEC filing on March 15, 2019.
Noble's colleagues
We found four more compensation records of executives who worked with James Noble at Adaptimmune Therapeutics in 2018.